Notes
The study was supported by Merck Sharp & Dohme.
Reference
Lorenzoni V, et al. Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. ClinicoEconomics and Outcomes Research : 20 Nov 2017. Available from: URL: https://doi.org/10.2147/CEOR.S141477
Rights and permissions
About this article
Cite this article
Sitagliptin add-on therapy cost saving for T2DM in Italy. PharmacoEcon Outcomes News 792, 28 (2017). https://doi.org/10.1007/s40274-017-4551-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4551-1